Related Experiment Videos
Age-related changes in melatonin levels in humans and its potential consequences for sleep disorders
F Waldhauser1, J Kovács, E Reiter
1Department of Pediatrics, University Hospital of Vienna, Austria. franz.waldhauser@akh-wien.ac.at
Insights
Melatonin (MLT) levels change throughout life, dropping significantly in childhood and adulthood. Research suggests MLT may promote sleep and could be a potential treatment for insomnia.
Area of Science:
- Endocrinology
- Sleep Medicine
- Chronobiology
Background:
- Melatonin (MLT) secretion begins after three months of age in humans, becoming circadian and peaking in early childhood.
- Nocturnal MLT levels decrease significantly during childhood and further in adulthood, particularly during senescence.
- The biological significance of these MLT level alterations and their role in sleep regulation remain largely unknown.
Purpose of the Study:
- To investigate the changes in melatonin secretion across different human age groups.
- To explore the potential role of melatonin in sleep promotion and its therapeutic implications for insomnia.
Main Methods:
- Observational analysis of melatonin secretion patterns across human lifespan.
- Review of recent studies investigating the effects of melatonin on sleep initiation, maintenance, and architecture.
Main Results:
- Human melatonin production starts after three months, peaks between ages one to three years, and declines progressively thereafter.
- Significant reductions in nocturnal melatonin levels are observed during childhood (80% drop) and adulthood (additional 10% drop).
- Melatonin demonstrates sleep-promoting effects, including accelerated sleep initiation and improved sleep maintenance, with potential efficacy at physiological concentrations.
Conclusions:
- Melatonin levels undergo substantial age-related changes, with potential implications for sleep regulation.
- Melatonin shows promise as a therapeutic agent for insomnia, even at physiological concentrations.
- Further research is warranted to elucidate the precise role of melatonin in the physiological control of sleep.
Abstract:
Prior to three months of age there is little melatonin (MLT) secretion in humans. MLT production then commences, becomes circadian, and reaches its highest nocturnal blood levels between the ages of one to three years. During the remainder of childhood, nocturnal peak levels drop progressively by 80%. In adults, these levels show an additional drop of some 10%, mainly during senescence. The large drop in serum MLT during childhood is probably the result of the increase in size of the human body, despite a constant MLT production after infancy. The additional decline of MLT with higher age may be due to a yet unidentified physiological mechanism accompanying senescence. The biological significance of these MLT alterations remains unknown. Since the discovery of MLT, an immediate sedative action of this hormone has been known. A number of recent studies have demonstrated that MLT indeed exerts a sleep-promoting action by accelerating sleep initiation, improving sleep maintenance, and marginally altering sleep architecture. The potential of MLT in the treatment of insomnia is being explored, and the results are promising. Although in most of these studies pharmacological dosages of MLT have been used, preliminary data suggest that similar effects can also be achieved by physiological hormone concentrations. The latter observation raises the question of whether MLT might be involved in the physiological control of sleep.